Shao-Lee Lin, M.D., Ph.D.

New Capabilities

As of October 2026: Leading CUE-221 toward Phase 2b/3 and food allergy trials after positive Phase 2 results

Cue Biopharma's chronic hives drug CUE-221 hit its primary goal in a 145-patient Phase 2 trial, clearing the way for a registration-enabling study. At the highest dose, 54% of patients had complete resolution of hives at week 12, versus 11% on placebo. On its September 21 investor call, Cue said high-dose patients kept that complete response for 12 weeks after the last dose.

Updated Oct 6